21 October 2014, 7:20 am
No, we cannot treat our way out of the HIV epidemic, was the resounding sentiment of a panel of expert clinicians and the audience, at a debate held at the 2014 Southern African HIV Clinicians Conference in Cape Town, South Africa, last month. Professor Richard Chaisson of the Johns Hopkins University School of Medicine

20 October 2014, 5:30 pm
A single-tablet regimen containing the hepatitis C virus (HCV) nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir – the combination in Gilead Science's recently approved Harvoni pill – was well-tolerated and cured 97% of patients with HCV genotype 1 in the Phase 3 ION trials, researchers reported at the IDWeek 2014 meeting earlier this month in Philadelphia, United States. The advent of direct-acting antiviral agents has revolutionised treatment for chronic hepatitis C,

20 October 2014, 9:00 am
Low-level elevations in important markers of systemic inflammation are associated with the development of type-2 diabetes in people taking antiretroviral therapy (ART), investigators report in the online edition of the Journal of Acquired Immune Deficiency Syndromes. The authors examined the relationship between baseline levels of high sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6) and incident

16 October 2014, 12:00 pm
The Steering Committee* of the PROUD trial of pre-exposure prophylaxis (PrEP) in gay men in England announced today that participants currently on the deferred arm of the study, who have not yet started PrEP, will be recalled to their clinics and offered the opportunity to begin PrEP ahead of schedule. This is because

16 October 2014, 8:00 am
Of the people living with HIV in South Africa who are eligible to start antiretroviral therapy (ART), only 57% are in care and only 37% of the 2012/2013 cohort of people receiving ART were given a viral load test, according to new results announced by the CEO of the South African National AIDS

1 2

    • No upcoming events
  • View All Add your news